

Global Wellness Strategies Inc. (formerly Redfund Capital Corp.)

Condensed Consolidated Interim Financial Statements

For the three months ended

December 31, 2020

Unaudited – Prepared by Management

(Expressed in Canadian Dollars)

NOTICE OF NO AUDITOR REVIEW OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

The accompanying unaudited condensed consolidated interim financial statements of Global Wellness Strategies Inc. (formerly Redfund Capital Corp.) ("the Company") for the three months ended December 31, 2020 and December 31, 2019, have been prepared by the management of the Company and approved by the Company's Audit Committee and the Company's Board of Directors.

Under National Instrument 51-102, Part 4, subsection 4.3 (3) (a), if an auditor has not performed a review of the interim financial statements, they must be accompanied by a notice indicating that an auditor has not reviewed the financial statements.

The accompanying unaudited condensed consolidated interim financial statements of the Company have been prepared by and are the responsibility of the Company's management. The Company's independent auditor has not performed a review of these financial statements in accordance with standards established by CPA Canada for a review of the condensed consolidated interim financial statements by an entity's auditor.

Condensed Consolidated Interim Statements of Financial Position

(Unaudited - Prepared by management)

As at December 31, 2020 and September 30, 2020

		Note	December 31, 2020 \$	September 30, 2020 \$
Assets				
Current assets				
Cash			1,270	3,999
Total assets			1,270	3,999
Liabilities and shareholders' Current liabilities	deficit			
Accounts payable and accru	ed liabilities	7	305,679	264,654
Total liabilities			305,679	264,654
Shareholders' deficit				
Share capital		5	30,254,573	30,134,573
Reserves		5	6,529,801	6,529,801
Deficit			(37,088,783)	(36,925,029)
Total shareholders' deficit			(304,409)	(260,655)
Total liabilities and sharehol	ders' deficit		1,270	3,999
Nature of operations and go	oing concern	1		
Events after the reporting p	eriod	10)	
Approved on behalf of the E	Board of Directors on February	26, 2021:		
"Meris Kott"	Director	"Lindsev Perrv J	r." Direct	tor

"Meris Kott"	Director	"Lindsey Perry Ir "	Directo

Global Wellness Strategies Inc. (formerly Redfund Capital Corp.) Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficit) (Unaudited – Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

	Number of shares #	Share capital \$	Reserves	Deficit \$	Total shareholders' equity (deficit) \$
October 1, 2019	12,854,237	29,679,528	6,869,055	(35,938,796)	609,787
Shares issued for services	175,000	41,001	-	-	41,001
Loss and comprehensive loss for the year	-	-	-	(73,448)	(73,448)
December 31, 2019	13,029,237	29,720,529	6,869,055	(36,012,244)	577,340
October 1, 2020	14,750,560	30,134,573	6,529,801	(36,925,029)	(260,655)
Shares issued for services	1,000,000	120,000	-	-	120,000
Loss and comprehensive loss for the year	-	-	-	(163,754)	(163,754)
December 31, 2020	15,750,560	30,254,573	6,529,801	(37,088,783)	(304,409)

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

		December 31, 2020	December 31, 2019
	Note	\$	\$
Income			
Interest income		-	16,61
		-	16,61°
Expenses			
Bank charges		366	474
Consulting	7	150,000	37,402
Office and rent		-	4,395
Professional fees	7	11,025	7,442
Regulatory and filing		2,363	5,404
Travel	7	-	7,768
Loss from operating expenses		(163,754)	(46,274
Gain on contract settlement	5	-	24,000
Unrealized gain on convertible loans receivable, net	4	-	(51,107
Foreign exchange gain (loss)		-	(67
Net loss for the period		(163,754)	(73,448
Loss per share			
Weighted average number of common shares outstanding			
- Basic #	6	14,886,176	12,892,86
- Diluted #	6	14,886,176	12,892,867
Basic loss per share \$	6	(0.01)	(0.01
Diluted loss per share \$	6	(0.01)	(0.01

Condensed Consolidated Statements of Cash Flows

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

		December 31, 2020	December 31, 2019
	Note	\$	\$
Operating activities			
Net loss for the period		(163,754)	(73,448)
Adjustments for:			
Shares issued for services		120,000	41,001
Unrealized gain on convertible loans receivable, net		-	51,107
Net change in non-cash working capital items	8	41,025	(36,731)
		(2,729)	(18,071)
Net change in cash		(2,729)	(18,071)
Cash, beginning of period		3,999	18,280
Cash, end of period		1,270	209

Supplemental cash flow information

8

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

1. Nature of operations and going concern

Global Wellness Strategies Inc. (formerly Redfund Capital Corp.) (the "Company") was incorporated under the Business Corporation Act of Alberta on August 31, 1998 and was continued to British Columbia on January 30, 2006. The Company's shares are publicly traded on the Frankfurt Exchange, OTCQB and Canadian Stock Exchange (the "CSE") under the symbol "LOAN".

On August 2, 2018, the Company completed a change of business and corporate name change to become a merchant bank focused on medical cannabis non-THC, CBD and hemp in both Canada and the United States. The head office, principal address and records office of the Company are located at 100 - 1111 Melville St Vancouver, British Columbia V6E 3V6.

On January 22, 2021, the Company consolidated the Company's issued share capital on a ratio of four (4) old common shares for every one (1) new post-consolidated common share. All current and comparative references to the number of common shares, weighted average number of common shares, loss per share, stock options and warrants have been restated to give effect to this Share Consolidation. Additionally, the Company changed their name to Global Wellness Strategies Inc.

These condensed consolidated interim financial statements (the "financial statements") have been prepared on a going concern basis which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future. As at December 31, 2020, the Company is not able to finance day to day activities through operations and continues to incur losses. The continuing operations of the Company are dependent upon its ability to attain profitable operations and generate funds there from. This indicates the existence of a material uncertainty that may cast significant doubt about the Company's ability to continue as a going concern. Management intends to finance operating costs with equity financings, loans from directors and companies controlled by directors and or private placement of common shares. If the Company is unable to continue as a going concern, the net realizable value of its assets may be materially less than the amounts on its consolidated statement of financial position.

In March 2020 the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and any related adverse public health developments, has adversely affected workforces, economies, and financial markets globally, potentially leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company's business or ability to raise funds.

2. Significant accounting policies

(a) Basis of presentation

These financial statements have been prepared in conformity with International Accounting Standard ("IAS") 34, Interim Financial Reporting, using the same accounting policies as detailed in the Company's annual audited consolidated financial statements for the year ended September 30, 2020, and do not include all the information required for full annual financial statements in accordance with International Financial Reporting Standards ("IFRS"), as issued by the International Accounting Standards Board ("IASB") and interpretations of the International Financial Reporting Interpretations Committee ("IFRIC"). It is suggested that these financial statements be read in conjunction with the annual audited financial statements.

These financial statements have been prepared on an historical cost basis, except for financial instruments measured at fair value. In addition, these financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

All amounts in these financial statements are presented in Canadian dollars, which is the functional currency of the Company. See note 2(b) for functional currency details of the Company's subsidiaries.

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

2. Significant accounting policies (continued)

(b) Basis of consolidation

These financial statements include the accounts of the Company and its subsidiaries. The results of each subsidiary will continue to be included in the consolidated financial statements of the Company until the date that the Company's control over the subsidiary ceases. Control exists when the Company has the power, directly or indirectly, to govern the financial and operating policies of an entity so as to obtain benefits from its activities.

Inter-company balances and transactions, including unrealized income and expenses arising from inter-company transactions, are eliminated on consolidation.

Entity	Incorporation	Status	Functional Currency	Ownership Percentage
Ultra Invest Canada Inc. ("Ultra Invest")	Canada	Inactive	Canadian	100%
Ona Power Oil & Gas Corp ("Ona")	United States	Inactive	US Dollar	100%

(c) Future changes in accounting policies

A number of new standards, and amendments to standards and interpretations, are not yet effective for the three months ended December 31, 2020, and have not been applied in preparing the financial statements. These new standards are either not applicable or are not expected to have a significant impact on the Company's consolidated financial statements.

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited – Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

3. Acquisitions and investments

Mary's Wellness Ltd. ("MWL")

On March 20, 2019, the Company converted its \$100,000 convertible loan receivable to 5% of the common shares in MWL. The investment in MWL was recorded at cost as the Company does not have significant influence nor control over MWL. On September 30, 2019, due to the inability of the Company to obtain recent financial information of MWL and given the Company did not receive any returns from this investment, the Company had impaired this investment to \$nil, resulting in an impairment loss of \$100,000. The Company assessed the investment at December 30, 2020 and no reversal of impairment was noted.

Sunshine State Tea Company, LLC ("SSTC")

On February 6, 2020, the Company entered into a Limited Liability Company Membership Interest Purchase Agreement (the "Agreement") with SSTC, a private Florida, United States company controlled by the Company's CEO, Meris Kott, to purchase 18% membership interest in SSTC. The assets in SSTC include formulas related to SSTC tea product line.

On April 1, 2020, the Company issued 1,125,000 common shares to Meris Kott, to acquire an 18% membership interest of SSTC. As additional consideration of the transaction, the Company shall loan the sum of \$500,000 to SSTC for project and business development over the next 3 years, which the loan shall be repaid within 5 years from the date of the last funding and shall bear interest at 6% per annum. This acquisition has been accounted for as a asset acquisition as SSTC does not meet the definition of a business under *IFRS 3, Business Combinations*.

In accordance with *IFRS 2 – Share based payments*, the equity consideration on transfer was measured at fair value on the date of acquisition, which is the date control was obtained.

Consideration paid:	
1,125,000 common shares at \$0.24 per share	\$ 270,000

The fair value share consideration pertaining to the asset acquisition was \$270,000. The consideration paid was recognized as share-based payments in the amount of \$270,000 during the year ended September 30, 2020.

		Convertible debenture receivable		
			Face value	Fair value
Balance, September 30, 2019		\$	741,809	726,886
Biominerales Pharma Corp.				
	Loan balance		499,135	495,288
	Fair value adjustments		-	9,712
	Interest income received		(47,187)	-
	Interest income accrued		70,894	-
	Impairment of convertible receivable		(522,842)	(505,000)
			-	-
RxMM Health Capital Inc.				
	Loan balance		242,674	231,598
	Fair value adjustments		-	59,997
	Interest income accrued		30,988	-
	Impairment of convertible receivable		(273,662)	(291,595)
			-	-
Balance, September 30, 2020 a	nd December 31, 2020	\$	-	-

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

4. Convertible loans receivable (continued)

Biolog, Inc.

On August 21, 2018 ("Effective Date"), the Company subscribed for a convertible secured promissory note with Biolog, Inc. ("Biolog"), a private company incorporated in the State of Utah. The Company has agreed to advance up to USD\$800,000 in tranches. Advances are secured by the assets of Biolog and bear interest at 14%, payable monthly, and the promissory note is due on September 1, 2020. On the Effective Date, the Company advanced \$194,000. The note may be converted into common shares of Biolog at a price equal to a 10% discount to the valuation of Biolog immediately from any financing immediately prior to the date of conversion.

In addition, Biolog issued warrants equivalent to 20% of the amount of the note based upon its valuation as of the Effective Date which is stipulated to be USD\$10,000,000. The option to settle the convertible note and warrants in common shares of Biolog represents an embedded derivative in the form of a call option to the Company. Biolog is a private company and its shares cannot be reliably valued using any market-derived indicators. Accordingly, the derivative asset was initially recognized by the Company at \$nil value. As at September 30, 2019 and September 30, 2020, the fair value of the derivative asset remained the same.

Management completed a thorough analysis as to any expected credit losses on certain of its financial assets. Accordingly, management has been unable to review financial information of Biolog and has assessed the high likelihood of un-collectability in respect to the principal portion of the loan. Thus, the entire balance of convertible note receivable remains impaired. As such time the loan is repaid in full, the Company will recognize a recovery of the impairment amount. This loan continues to be secured by the borrowers' assets. As at September 30, 2020 and December 31, 2020, the loan was in default. The Company will be taking the steps of recovery through the borrowers' assets.

Biominerales Pharma Corp.

On August 27, 2018 ("Effective Date"), the Company subscribed for a convertible secured promissory note with Biominerales Pharma Corp. ("Biopharma"), a private company incorporated under the laws of the Province of Quebec. The Company has agreed to advance up to USD\$196,184. Advances are secured by the assets of Biopharma and bears interest at 14% annually, payable monthly; and the promissory note is due on October 1, 2020. On the Effective Date, the Company advanced \$255,000 under the note. The note may be converted into common shares of Biopharma at a price equal to a 10% discount to the price assigned to the common shares of Biopharma from any financing immediately prior to the date of conversion. The Company is not able to exert significant influence over the operations of Biopharma.

In addition, Biopharma issued 18,684 warrants, exercisable at a price of \$2.10 per warrant, to acquire one Class A common share in the capital of Biopharma for a period of 24 months. The option to settle the convertible note and the stock warrants in Class A common shares of Biopharma represents an embedded derivative in the form of a call option. Biopharma is a private company and its shares cannot be reliably valued using any market-derived indicators. As at September 30, 2018, the Company had not received repayment of such note and management has assessed the high likelihood of collectability. Thus, the entire balance of convertible note receivable had been impaired.

On October 1, 2018, a further \$250,000 was loaned to Biopharma under the same terms as the previously loaned \$255,000. This loan continues to be secured by the borrowers' assets. During the period ended September 30, 2020, Biopharma has made monthly interest payments in accordance with the promissory note totaling \$47,176.

Management completed a thorough analysis as to any expected credit losses on certain of its financial assets. Accordingly, management has not been satisfied through the review of financial information of Biominerales and has assessed the high likelihood of un-collectability in respect to the principal portion of the loan. Thus, the entire balance of convertible note receivable had been impaired \$505,000 as at September 30, 2020.

During the three months ended December 31, 2020, the Company extended the loan payable maturity date to May 1, 2021. Biopharma has not made monthly interest payments in accordance with the promissory note.

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

4. Convertible loans receivable (continued)

RxMM Health Capital Inc.

On October 1, 2018, the Company entered into a US\$500,000 promissory note with RxMM Health ("RxMM"). The loan is secured by a general security agreement on assets of RxMM. The loan bears an interest at 14% compounded monthly and is repayable within 24 months. Furthermore, RxMM granted additional consideration to the Company providing an option to purchase common shares of RxMM equal to 20% of the amount of the loan based on a valuation agreed upon between RxMM and the Company. On October 9, 2018, the Company made a first tranche loan of \$220,740 CDN to RxMM. This loan continues to be secured by the borrowers' assets.

Management completed a thorough analysis as to any expected credit losses on certain of its financial assets. Accordingly, management has been unable to review financial information of RxMM and has assessed the high likelihood of un-collectability in respect to the principal portion of the loan. Thus, the entire balance of convertible note receivable has been impaired. As such time the loan is repaid in full, the Company will recognize a recovery of the impairment amount. This loan continues to be secured by the borrowers' assets. As at September 30, 2020 and December 31, 2020, the loan was in default. The Company will be taking the steps of recovery through the borrowers' assets.

Mary's Wellness Ltd.

On October 15, 2018, the Company entered into a \$1,000,000 promissory note with Mary's Wellness Ltd. ("MWL"). The loan was secured by a general security agreement on assets of MWL. The loan bore an interest rate of 12.5% per annum compounded monthly and was repayable by November 1, 2020. Furthermore, MWL granted additional consideration to the Company providing an option to purchase common shares of MWL equal to 20% of the amount of the loan based on a valuation agreed upon between MWL and the Company. On October 19, 2018, the Company made a first tranche loan of \$100,000 CDN to MWL. This loan was secured by the borrowers' assets. The entire loan was converted on March 20, 2019 to a 5% equity interest in MWL (Note 3).

Winterlife Inc.

On November 1, 2018, the Company entered into a USD\$1,000,000 promissory note with Winterlife Inc. ("Winterlife"). The loan is secured by a general security agreement on assets of Winterlife made effective on November 1, 2018. The loan bears an interest rate of 14% per annum compounded monthly and is repayable by November 1, 2020. Furthermore, Winterlife granted additional consideration to the Company providing an option to purchase common shares of Winterlife equal to 20% of the amount of the loan based on a valuation agreed upon between Winterlife and the Company. On November 6, 2018, the Company made a first tranche loan of \$100,080 CDN to Winterlife. This loan continues to be secured by the borrowers' assets.

Management completed a thorough analysis as to any expected credit losses on certain of its financial assets. Accordingly, management has been unable to review financial information of Winterlife and has assessed the high likelihood of un-collectability in respect to the principal portion of the loan. Thus, the entire balance of convertible note receivable has been impaired. As such time the loan is repaid in full, the Company will recognize a recovery of the impairment amount. This loan continues to be secured by the borrowers' assets. As at September 30, 2020 and December 31, 2020, the loan was in default. The Company will be taking the steps of recovery through the borrowers' assets.

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

5. Share capital

The authorized share capital of the Company consists of unlimited common shares without par value and unlimited preferred shares without par value. All issued shares are fully paid.

Transactions for the issue of share capital during the three months ended December 31, 2020:

The Company issued a total of 1,000,000 shares to consultants on the following dates for consulting services rendered:

- November 10, 2020: 500,000 shares for \$60,000 (\$0.12 per share); and
- November 11, 2020: 500,000 shares for \$60,000 (\$0.12 per share).

The fair value of the above share issuances was recognized and included in consulting expenses. No gain of loss was recognized in respect of any of the shares issued for services during the year.

Transactions for the issue of share capital during the three months ended December 31, 2019:

The Company issued a total of 175,000 shares to consultants on the following dates for consulting services rendered:

- October 2, 2019: 125,000 shares for \$25,001 (\$0.20 per share); and
- November 4, 2019: 50,000 shares for \$16,000 (\$0.32 per share).

The above share issuances were included in consulting expenses. In connection with the shares issued for services, the Company recognized a gain on contract settlement in the amount of \$24,000.

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

5. Share capital (continued)

Stock options

The Company has adopted a stock option plan (the "Plan") whereby the Company may from time to grant to Directors, Officers, employees and consultants options to purchase common shares of the Company provided that the number of options granted, including all options granted by the Company to date, does not exceed 10% of the Company's common shares issued and outstanding at the time of granting stock options. Options may be exercised no later than 90 days following cessation of the optionee's position with the Company or 30 days following cessation of an optionee conducting investor relations activities' position.

A summary of the status of the Company's stock options as at December 31, 2020 and September 30, 2020, and changes during the period/year then ended is as follows:

	Three months ended December 31, 2020		Year ended September 30, 2020	
		Weighted average		Weighted average
	Options	exercise price	Options	exercise price
	#	\$	#	\$
Options outstanding, beginning of period/year	487,500	0.47	337,500	1.74
Granted	-	-	422,500	0.34
Expired/cancelled	-	-	(272,500)	1.84
Options outstanding, end of period/year	487,500	0.47	487,500	0.47

As at December 31, 2020 the Company has stock options outstanding and exercisable as follows:

Options outstanding #	Options exercisable #	Exercise price \$	Expiry date
21,250	21,250	2.04	October 12, 2023 *
75,000	75,000	0.68	September 6, 2024
25,000	25,000	0.68	November 19, 2024
328,750	328,750	0.32	May 14, 2025
37,500	37,500	0.32	May 20, 2025
 487,500	487,500		

^{*} Cancelled subsequent to the period ended December 31, 2020

The following table summarizes information about the stock options outstanding as at December 31, 2020:

Number of	Weighted	Weighted
options	average	average
outstanding	remaining life	exercise price
#	(years)	\$
487,500	4.17	0.47

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

5. Share capital (continued)

Stock options (continued)

On November 19, 2019, the Company granted 25,000 options to a Director of the Company. Each option is exercisable into one common share of the Company for \$0.68 per share and expires November 19, 2024. These options had a fair value on grant of \$5,500 using the Black-Scholes option pricing model with the following assumptions: i) exercise price: \$0.68; ii) share price: \$0.34; iii) term: 5 years; iv) volatility: 100%; v) risk-free rate: 1.45%.

On May 14, 2020, the Company granted 360,000 options to Officers, Directors, and consultants of the Company. Each option is exercisable into one common share of the Company for \$0.32 per share and expires May 14, 2025. These options had a fair value on grant of \$42,600 using the Black-Scholes option pricing model with the following assumptions: i) exercise price: \$0.32; ii) share price: \$0.18; iii) term: 5 years; iv) volatility: 100%; v) risk-free rate: 0.36%.

On May 20, 2020, the Company granted 37,500 options to Officers, Directors, and consultants of the Company. Each option is exercisable into one common share of the Company for \$0.32 per share and expires May 20, 2025. These options had a fair value on grant of \$5,100 using the Black-Scholes option pricing model with the following assumptions: i) exercise price: \$0.32; ii) share price: \$0.20; iii) term: 5 years; iv) volatility: 100%; v) risk-free rate: 0.41%.

Warrants

As an incentive to complete private placements, the Company may issue units which include common shares and common share purchase warrants. Using the residual value method, the Company determines whether a value should be allocated to the warrants attached to the units sold in completed private placements.

Finders' warrants may be issued as a private placement share issue cost and are valued using the Black-Scholes option pricing model.

A summary of the status of the Company's warrants as at December 31, 2020 and September 30, 2020, and changes during the period/year then ended is as follows:

	Three months ended December 31, 2020		Year ended September 30, 2020	
	Warrants #	Weighted average exercise price	Warrants #	Weighted average exercise price
Warrants outstanding, beginning of period/year	3,214,395	1.29	5,992,575	1.32
Private placement warrants expired	(1,436,617)	2.20	(2,778,180)	1.36
Warrants outstanding, end of period/year	1,777,778	0.56	3,214,395	1.29

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited – Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

Share capital (continued)

Warrants (continued)

As at December 31, 2020 the Company had private placement warrants outstanding and exercisable as follows:

	Warrants outstanding #	Exercise price \$	Expiry date
_	888,889	0.56	January 8, 2021 *
	888,889	0.56	August 16, 2021
	1,777,778		

Expired unexercised subsequent to the period ended December 31, 2020

The following table summarizes information about the warrants outstanding as at December 31, 2020:

	Number of	Weighted	Weighted	
Range	warrants	average	average	
of prices	outstanding	remaining life	exercise price	
\$	#	(years)	\$	
0.56	1,777,778	0.32	0.56	
	1,777,778	0.32	0.56	

6. Loss per share

The calculation of basic and diluted loss per share for the year ended December 31, 2020 was based on the loss attributable to common shareholders of \$163,754 (2019 - \$73,448) and a weighted average number of common shares outstanding of 14,886,176 (2019 – 12,892,867).

All options and warrants were excluded from the diluted weighted average number of common shares calculation, as their effect would have been anti-dilutive.

7. Related party payables and transactions

A number of key management personnel and directors hold positions in other entities that result in them having control or significant influence over the financial or operating policies of these entities. There were no loans to management personnel or Directors, or entities over which they have control or significant influence, during the three months ended December 31, 2020 or December 31, 2019.

Meris Kott, the Company's President and CEO receives a monthly consulting fee and incentive stock options. All other key management personnel and directors receive no salaries, non-cash benefits (other than incentive stock options), or other remuneration directly from the Company, other than noted below, and there are no employment contracts with them that cannot be terminated without penalty on thirty days notice. Key management personnel and directors participate in the Company's stock option plan.

No stock options were granted during the three months ended December 31, 2020. During the three months ended December 31, 2019, the Company granted 25,000 stock options to a director of the Company which had a deemed fair value of \$5,500.

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

7. Related party payables and transactions (continued)

The Company transacted with the following related parties:

- (a) 1060606 BC Ltd. ("106 BC Ltd.") is a consulting firm over which the CEO of the Company has significant influence and ownership. Charges are for consulting, travel, office rent and administration.
- (c) Stephen Brohman is the Company's CFO. He is a principal of Donaldson Brohman Martin CPA Inc. ("DBM CPA"), a firm in which he has significant influence. DBM CPA provides the Company with professional services.

The aggregate value of transactions and outstanding balances with key management personnel and Directors and entities over which they have control or significant influence were as follows:

	Transactions 3 months ended December 31, 2020 \$	Transactions 3 months ended December 31, 2019 \$	Balances outstanding December 31, 2020 \$	Balances outstanding September 30, 2020 \$
106 BC Ltd.		·	•	
- consulting services	30,000	37,402	119,991	89,991
- travel	-	7,768	-	-
	30,000	45,170	119,991	89,991
DBM CPA	10,500	-	42,925	32,425
Meris Kott	-	-	17,150	17,150
_	40,500	45,170	180,066	139,566

All related party balances are unsecured and are due within thirty days without interest.

The transactions with the key management personnel and Directors are included in operating expenses as follows:

- (a) Consulting and travel expenses
 - Includes Meris Kott fee related to consulting, administrative and travel related expenses.
- (b) Professional fees
 - Includes the accounting services of the Company's current CFO, Stephen Brohman, charged to the Company by DBM CPA.

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

8. Supplemental cash flow information

Changes in non-cash operating working capital during the three months ended December 31, 2020 and December 31, 2019 were comprised of the following:

	December 31,	December 31,	
	2020	2019	
	\$	\$	
Receivables and prepayments	-	(4,173)	
Accounts payable and accrued liabilities	41,025	(32,558)	
Net change	41,025	(36,731)	

During the three months ended December 31, 2020 and December 31, 2019 there were no amounts paid on account of interest or income taxes.

9. Financial risk management

Capital management

The Company is a merchant bank and considers items included in shareholders' equity as capital. The Company manages its capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of underlying assets. In order to maintain or adjust its capital structure, the Company may issue new shares, purchase shares for cancellation pursuant to normal course issuer bids or make special distributions to shareholders. The Company is not subject to any externally imposed capital requirements and does not presently utilize any quantitative measures to monitor its capital. The Company's capital structure as at December 31, 2020 is comprised of shareholders' deficit of \$304,409 (September 30, 2020 - \$260,655). There were no changes to the Company's management of capital during the three months ended December 31, 2020.

The Company currently has no source of revenues except for interest received from convertible loans. In order to fund future projects and pay for administrative costs, the Company will spend its existing working capital and raise additional funds as needed. The Company's ability to continue as a going concern on a long-term basis and realize its assets and discharge its liabilities in the normal course of business rather than through a process of forced liquidation is primarily dependent upon its ability to borrow or raise additional financing from equity markets.

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

9. Financial risk management (continued)

Financial instruments - fair value

The Company's financial instruments consist of cash, and accounts payable and accrued liabilities.

The carrying value of accounts payable and accrued liabilities approximates their fair value because of the short-term nature of these instruments.

Financial instruments measured at fair value on the statements of financial position are summarized into the following fair value hierarchy levels:

Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

	Level 1 \$	Level 2 \$	Level 3 \$	Total \$
December 31, 2020				
Cash	1,270	-	-	1,270
	1,270	-	-	1,270
September 30, 2020				
Cash	3,999	-	-	3,999
	3,999	-	-	3,999

Financial instruments - risk

The Company's financial instruments are exposed to certain financial risks, including credit risk, interest rate risk, market risk, and liquidity risk.

a) Credit risk

Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company's primary exposure to credit risk is on its bank account. All of its cash is deposited in a bank account held with a major bank in Canada. As most of the Company's cash is held by one bank there is a concentration of credit risk. This risk is managed by using a major bank that is a high credit quality financial institution as determined by rating agencies. The maximum exposure to credit risk is the carrying amount of the Company's financial instruments.

b) Foreign exchange risk

Foreign currency risk is the risk that the fair values of future cash flows of a financial instrument will fluctuate because they are denominated in currencies that differ from the respective functional currency. The Company is not exposed to significant foreign exchange risk.

c) Liquidity risk

Liquidity risk arises through the excess of financial obligations over available financial assets due at any point in time. The Company's objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements at any point in time.

Historically, the Company's main source of funding has been the issuance of equity securities for cash, primarily through private placements. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding.

Notes to the Condensed Consolidated Interim Financial Statements

(Unaudited - Prepared by management)

For the three months ended December 31, 2020 and December 31, 2019

10. Events after the reporting period

- a) On January 13, 2021, the Company issued a total of 104,166 shares to an officer for professional services rendered. These shares have a fair value, calculated using the market price at issuance date of \$0.22, of \$22,917.
- b) On February 25, 2021, the Company announced the resignation of one of its Directors, Eugene Hodgson. Additionally, the Company announced the issue of 250,000 options to certain Directors and Officers of the Company. These options are exercisable at a price of \$0.255 for a period of five years and vest immediately.